Richard Aplenc

faculty photo
Associate Professor of Pediatrics at the Children's Hospital of Philadelphia
Section Chief, Hematologic Malignancies, The Children's Hospital of Philadelphia
Associate Physician, The Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
CTRB Room 4018
3501 Civic Center Blvd
Philadelphia, PA 19104
Office: 2674267252
A.B. (Classics)
Princeton University, 1988.

University of Pennsylvania, Post-Baccalaureate Pre-Health Program, 1989.
University of Virginia, 1994.
MSCE (Clinical Epidemiology and Biostatistics)
University of Pennsylvania, 2002.
PhD (Epidemiology)
University of Pennsylvania, 2011.
Permanent link

Description of Itmat Expertise

Dr. Aplenc's research involves molecular epidemiology, pediatric cancer Phase I clinical trials, treatment of pediatric AML, and the use of genetic polymorphism data to predict treatment response to therapeutic interventions, particularly in pediatric cancer therapy.

Selected Publications

Miller T. P., Li Y., Kavcic M., Troxel A. B., Huang Y. S., Sung L., Alonzo T. A., Gerbing R. B., Hall M., Daves M. H., Horton T. M., Pulsipher M. A., Pollard J., Bagatell R., Seif A. E., Fisher B. T., Luger S. M., Gamis A. S., Adamson P. C., Aplenc R. : Accuracy of adverse event ascertainment on clinical trials for pediatric acute myeloid leukemia. J Clin Oncol 34(13): 1537-43, May 2016.

Teachey D. T., Lacey S. F., Shaw P. A., Melenhorst J. J., Maude S. L., Frey N., Pequignot E., Gonzalez V. E., Chen F., Finklestein J., Barrett D. M., Weiss S. L., Fitzgerald J. C., Berg R. A., Aplenc R., Callahan C., Rheingold S. R., Zheng Z., Rose-John S., White J. C., Nazimuddin F., Wertheim G., Levine B. L., June C. H., Porter D. L., Grupp S. A.: Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov Apr 2016.

Heneghan M. B., Rheingold S. R., Li Y., Seif A. E., Huang Y. S., McLeod L., Wells L., Fisher B. T., Aplenc R.: Treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 16(4): 223-229, Apr 2016.

DiNofia A. M., Salazar E., Seif A. E., Li Y., Huang Y. S., Bagatell R., Fisher B. T., Aplenc R.: Bortezomib inpatient prescribing practices in free-standing children's hospitals in the United States. PLoS One 11(3), Mar 2016.

Sung L., Dix D., Cellot S., Gillmeister B., Ethier M. C., Roslin N. M., Johnston D. L., Feusner J., Mitchell D., Lewis V., Aplenc R., Yanofsky R., Portwine C., Price V., Zelcer S., Silva M., Bowes L., Michon B., Stobart K., Traubici J., Allen U., Beyene J., den Hollander N., Paterson A. D.: Single nucleotide polymorphism in IL1B is associated with infection risk in paediatric acute myeloid leukaemia. Clin Microbiol Infect Feb 2016.

Miller T. P., Getz K. D., Kavcic M., Li Y., Huang Y. V., Sung L., Alonzo T. A., Gerbing R., Daves M., Horton T. M., Pulsipher M. A., Pollard J., Bagatell R., Seif A. E., Fisher B. T., Gamis A. S., Aplenc R.: A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: A report from the Children's Oncology Group. Leuk Lymphoma Page: 1-8, Jan 2016.

Pollard J. A., Loken M., Gerbing R. B., Raimondi S. C., Hirsch B. A., Aplenc R., Bernstein I. D., Gamis A. S., Alonzo T. A., Meshinchi S.: CD33 expression and its association with gemtuzumab ozogamicin response: Results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol Jan 2016.

Desai A. V., Seif A. E., Li Y., Getz K., Fisher B. T., Huang V., Mante A., Aplenc R., Bagatell R.: Resource utilization and toxicities after carboplatin/etoposide/melphalan and busulfan/melphalan for autologous stem cell rescue in high-risk neuroblastoma using a national administrative database. Pediatr Blood Cancer Jan 2016.

Lee G. E., Fisher B. T., Xiao R., Coffin S. E., Feemster K., Seif A. E., Bagatell R., Li Y., Huang Y. S., Aplenc R.: Burden of influenza-related hospitalizations and attributable mortality in pediatric acute lymphoblastic leukemia. J Pediatric Infect Dis Soc 4(4): 290-6, Dec 2015.

Tarlock K., Alonzo T. A., Gerbing R., Raimondi S. C., Hirsch B. A., Sung L., Pollard J. A., Aplenc R., Loken M. R., Gamis A., Meshinchi S.: Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. Clin Cancer Res Dec 2015.

back to top
Last updated: 04/30/2016
The Trustees of the University of Pennsylvania